56
Participants
Start Date
May 25, 2021
Primary Completion Date
June 20, 2023
Study Completion Date
June 26, 2024
ABL001
Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
Wake Forest University Baptist Medical Center, Winston-Salem
Florida Cancer Specialists Pan, Tallahassee
Memorial Cancer Institute, Hollywood
Florida Cancer Specialists-North, St. Petersburg
Florida Cancer Specialists, Sarasota
Florida Cancer Specialists East, Stuart
University of Kentucky, Lexington
Uni of Cincinnati Medical Center, Cincinnati
Oncology Hematology Care Inc, Cincinnati
Indiana Blood and Marrow Institute, Beech Grove
Medical College of Wisconsin, Milwaukee
Siteman Cancer Center, St Louis
Texas Oncology, Dallas
Texas Oncology Northeast Texas, Tyler
Texas Oncology P A, Fort Worth
Univ of TX MD Anderson Cancer Cntr, Houston
Rocky Mountain Cancer Centers, Boulder
Arizona Oncology Associates, Phoenix
Cancer Treatment Centers of America, Phoenix
Pacific Shores Medical Group, Long Beach
Northwest Cancer Specialists, Portland
Alaska Oncology and Hematology, Anchorage
Lundquist Inst BioMed at Harbor, Torrance
Uni of Massachusetts Medical Center, Worcester
Michigan Med University of Michigan, Ann Arbor
Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY